Quinolinic acid, the inescapable neurotoxin

Over the last two decades, evidence for the involvement of quinolinic acid (QUIN) in neuroinflammatory diseases has been exponentially increasing. Within the brain, QUIN is produced and released by infiltrating macrophages and activated microglia, the very cells that are prominent during neuroinflammation. QUIN acts as an agonist of the N‐methyl‐d‐aspartate receptor and as such is considered to be a brain endogenous excitotoxin. Since the discovery of the excitotoxic activity of QUIN in the early 1980s, several other cytotoxic mechanisms have been identified. We know today that QUIN acts as a neurotoxin, gliotoxin, proinflammatory mediator, pro‐oxidant molecule and can alter the integrity and cohesion of the blood–brain barrier. This paper aims to review some of the most recent findings about the effects of QUIN and its mode of action.

[1]  B. Bogerts,et al.  Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood–brain barrier integrity , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[2]  B. Brew,et al.  The kynurenine pathway and quinolinic acid: pivotal roles in HIV associated neurocognitive disorders , 2012, The FEBS journal.

[3]  T. Stone,et al.  Kynurenine pathway inhibition as a therapeutic strategy for neuroprotection , 2012, The FEBS journal.

[4]  A. Myint.  Kynurenines: from the perspective of major psychiatric disorders , 2012, The FEBS journal.

[5]  B. Brew,et al.  Characterization of the kynurenine pathway in NSC‐34 cell line: implications for amyotrophic lateral sclerosis , 2011, Journal of neurochemistry.

[6]  H. Ball,et al.  Overexpression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase in triple-transgenic (3xTg) Alzheimer's disease mouse brain , 2011, Alzheimer's & Dementia.

[7]  M. Herrero,et al.  The Involvement of Neuroinflammation and Kynurenine Pathway in Parkinson's Disease , 2011, Parkinson's disease.

[8]  Kazuo Suzuki,et al.  Interferon-γ Regulates the Proliferation and Differentiation of Mesenchymal Stem Cells via Activation of Indoleamine 2,3 Dioxygenase (IDO) , 2011, PloS one.

[9]  B. Brew,et al.  Characterisation of the Expression of NMDA Receptors in Human Astrocytes , 2010, PloS one.

[10]  V. Meininger,et al.  The Kynurenine Pathway and Inflammation in Amyotrophic Lateral Sclerosis , 2010, Neurotoxicity Research.

[11]  T. M. Souza,et al.  Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats , 2010, Experimental Neurology.

[12]  J. Stasch,et al.  Kynurenine is an endothelium-derived relaxing factor produced during inflammation , 2010, Nature Medicine.

[13]  Paolo Guidetti,et al.  Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease , 2010, Progress in Neurobiology.

[14]  J. Arthur,et al.  Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2 , 2010, Amino Acids.

[15]  B. Brew,et al.  Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder , 2010, International journal of tryptophan research : IJTR.

[16]  N. Braidy,et al.  Neuroprotective effects of naturally occurring polyphenols on quinolinic acid‐induced excitotoxicity in human neurons , 2010, The FEBS journal.

[17]  B. Brew,et al.  Understanding the Roles of the Kynurenine Pathway in Multiple Sclerosis Progression , 2010, International journal of tryptophan research : IJTR.

[18]  B. Brew,et al.  Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease , 2009, Journal of Neuroinflammation.

[19]  Gilles J. Guillemin,et al.  The Excitotoxin Quinolinic Acid Induces Tau Phosphorylation in Human Neurons , 2009, PloS one.

[20]  B. Brew,et al.  Mechanism for Quinolinic Acid Cytotoxicity in Human Astrocytes and Neurons , 2009, Neurotoxicity Research.

[21]  H. Ball,et al.  Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. , 2009, The international journal of biochemistry & cell biology.

[22]  G. Smythe,et al.  Age and circadian influences on picolinic acid concentrations in human cerebrospinal fluid , 2009, Journal of neurochemistry.

[23]  V. Meininger,et al.  Recent advances in the treatment of amyotrophic lateral sclerosis. Emphasis on kynurenine pathway inhibitors. , 2009, Central nervous system agents in medicinal chemistry.

[24]  G. Guillemin,et al.  Kynurenine Pathway Metabolites in Humans: Disease and Healthy States , 2009, International journal of tryptophan research : IJTR.

[25]  B. Brew,et al.  Effects of Kynurenine Pathway Metabolites on Intracellular NAD+ Synthesis and Cell Death in Human Primary Astrocytes and Neurons , 2009, International journal of tryptophan research : IJTR.

[26]  B. Brew,et al.  Kynurenine pathway metabolism in human blood–brain–barrier cells: implications for immune tolerance & neurotoxicity , 2008, Journal of neurochemistry.

[27]  B. Brew,et al.  The involvement of astrocytes and kynurenine pathway in Alzheimer’s disease , 2007, Neurotoxicity Research.

[28]  Gilles J Guillemin,et al.  Characterization of the Kynurenine Pathway in Human Neurons , 2007, The Journal of Neuroscience.

[29]  B. Brew,et al.  Characterization of the kynurenine pathway in human oligodendrocytes , 2007 .

[30]  J. Pedraza-Chaverri,et al.  Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. , 2007, Neurotoxicology.

[31]  L. Steinman,et al.  Anti-inflammatory strategies for the treatment of multiple sclerosis – tryptophan catabolites may hold the key , 2006 .

[32]  V. Meininger,et al.  Implications for the Kynurenine Pathway and Quinolinic Acid in Amyotrophic Lateral Sclerosis , 2006, Neurodegenerative Diseases.

[33]  B. Brew,et al.  Indoleamine 2,3 dioxygenase and quinolinic acid Immunoreactivity in Alzheimer's disease hippocampus , 2005, Neuropathology and applied neurobiology.

[34]  P. Klivényi,et al.  Kynurenine metabolism in multiple sclerosis , 2005, Acta neurologica Scandinavica.

[35]  B. Brew,et al.  Quinolinic acid selectively induces apoptosis of human astrocytes: potential role in AIDS dementia complex , 2005, Journal of Neuroinflammation.

[36]  T. Stone,et al.  Tryptophan metabolism and oxidative stress in patients with Huntington's disease , 2005, Journal of neurochemistry.

[37]  U. Kumar.  Characterization of striatal cultures with the effect of QUIN and NMDA , 2004, Neuroscience Research.

[38]  R. Yolken,et al.  Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia , 2004, Neurobiology of Disease.

[39]  E. Ragazzi,et al.  Enzyme activities of tryptophan metabolism along the kynurenine pathway in various species of animals. , 2003, Farmaco.

[40]  B. Brew,et al.  Quinolinic acid upregulates chemokine production and chemokine receptor expression in astrocytes , 2003, Glia.

[41]  B. Brew,et al.  Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease , 2002, Redox report : communications in free radical research.

[42]  T. Stone,et al.  Endogenous kynurenines as targets for drug discovery and development , 2002, Nature Reviews Drug Discovery.

[43]  T. Stone,et al.  The pharmacological manipulation of glutamate receptors and neuroprotection. , 2002, European journal of pharmacology.

[44]  D. Souza,et al.  Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes , 2002, Neurochemistry International.

[45]  T. Stone,et al.  Enhanced neuronal damage by co‐administration of quinolinic acid and free radicals, and protection by adenosine A2A receptor antagonists , 2002, British journal of pharmacology.

[46]  A. Camacho,et al.  In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum , 2001, Neuroreport.

[47]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection , 2001, Journal of neurochemistry.

[48]  S. Mandel,et al.  Gene expression analysis in N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R‐apomorphine , 2001, Journal of neurochemistry.

[49]  A. Santamaría,et al.  Quinolinic acid induces oxidative stress in rat brain synaptosomes , 2001, Neuroreport.

[50]  J. Penney,et al.  The Role of Group I and Group II Metabotropic Glutamate Receptors in Modulation of Striatal NMDA and Quinolinic Acid Toxicity , 2001, Experimental Neurology.

[51]  P. Stopka,et al.  Quinolinic acid — Iron(II) complexes: Slow autoxidation, but enhanced hydroxyl radical production in the Fenton reaction , 2001, Free radical research.

[52]  M. Raiteri,et al.  N‐Methyl‐d‐aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV‐1 envelope protein gp120, external pH and protein kinase C inhibition , 2001, Journal of neurochemistry.

[53]  D. Jezova,et al.  Quinolinic acid enhances permeability of rat brain microvessels to plasma albumin , 2000, Brain Research Bulletin.

[54]  D. Souza,et al.  Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain , 2000, Neuroreport.

[55]  T. Stone,et al.  Oxidative stress as a mechanism for quinolinic acid‐induced hippocampal damage: protection by melatonin and deprenyl , 1999, British journal of pharmacology.

[56]  R. Schwarcz,et al.  3‐Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum , 1999, The European journal of neuroscience.

[57]  F. Moroni,et al.  Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites. , 1999, European journal of pharmacology.

[58]  M. Takemura,et al.  Species differences in L-tryptophan-kynurenine pathway metabolism: quantification of anthranilic acid and its related enzymes. , 1998, Archives of biochemistry and biophysics.

[59]  A. Morton,et al.  Changes in blood–brain barrier permeability following neurotoxic lesions of rat brain can be visualised with trypan blue , 1998, Journal of Neuroscience Methods.

[60]  Dennis P. Nelson,et al.  Energetic Dysfunction in Quinolinic Acid‐Lesioned Rat Striatum , 1997, Journal of neurochemistry.

[61]  K. Kawai,et al.  Species Heterogeneity Between Gerbils and Rats: Quinolinate Production by Microglia and Astrocytes and Accumulations in Response to Ischemic Brain Injury and Systemic Immune Activation , 1997, Journal of neurochemistry.

[62]  B. Brew,et al.  Quinolinic Acid Production by Macrophages Stimulated with IFN-γ, TNF-α, and IFN-α , 1997 .

[63]  E. Major,et al.  Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. , 1997, The Biochemical journal.

[64]  J. Moffett,et al.  Quinolinate Immunoreactivity in Experimental Rat Brain Tumors Is Present in Macrophages but Not in Astrocytes , 1997, Experimental Neurology.

[65]  C. Colton,et al.  Activated human microglia produce the excitotoxin quinolinic acid , 1997, Neuroreport.

[66]  T. Zima,et al.  The effect of quinolinate on rat brain lipid peroxidation is dependent on iron , 1996, Neurochemistry International.

[67]  H. Saito,et al.  3-Hydroxykynurenine toxicity on the rat striatum in vivo. , 1996, Japanese journal of pharmacology.

[68]  N. Botting.  Chemistry and neurochemistry of the kynurenine pathway of tryptophan metabolism , 1996 .

[69]  E. Grasbon-Frodl,et al.  Antioxidant treatment protects striatal neurons against excitotoxic insults , 1996, Neuroscience.

[70]  R. Stocker,et al.  Nitric oxide inhibits indoleamine 2,3-dioxygenase activity in interferon-gamma primed mononuclear phagocytes. , 1994, The Journal of biological chemistry.

[71]  D. Longo,et al.  Interleukin-4 inhibits indoleamine 2,3-dioxygenase expression in human monocytes. , 1994, Blood.

[72]  T. Stone,et al.  Neuropharmacology of quinolinic and kynurenic acids. , 1993, Pharmacological reviews.

[73]  A. Schurr,et al.  Quinolinate potentiates the neurotoxicity of excitatory amino acids in hypoxic neuronal tissue in vitro , 1993, Brain Research.

[74]  T. Stone.  Subtypes of NMDA receptors. , 1993, General pharmacology.

[75]  E. Major,et al.  Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. , 1992, The Biochemical journal.

[76]  R. Schwarcz,et al.  Immunohistochemical localization of quinolinic acid phosphoribosyltransferase in the human neostriatum , 1991, Neuroscience.

[77]  A. Santamaría,et al.  Quinolinic acid is a potent lipid peroxidant in rat brain homogenates , 1991, Neurochemical Research.

[78]  M. Beal,et al.  Kynurenine Pathway Measurements in Huntington's Disease Striatum: Evidence for Reduced Formation of Kynurenic Acid , 1990, Journal of neurochemistry.

[79]  R. Schwarcz,et al.  Distribution of quinolinic acid phosphoribosyltransferase in the human hippocampal formation and parahippocampal gyrus , 1990, The Journal of comparative neurology.

[80]  J. C. Stoof,et al.  The quinolinic acid hypothesis in Huntington's chorea , 1990, Journal of the Neurological Sciences.

[81]  T. Guilarte,et al.  Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line , 1989, Brain Research.

[82]  P. Mcgeer,et al.  Effect of MK-801, kynurenate, glycine, dextrorphan and 4-acetylpyridine on striatal toxicity of quinolinate , 1989, Brain Research.

[83]  R. Beninger,et al.  Kynurenic acid protects against the neurochemical and behavioral effects of unilateral quinolinic acid injections into the nucleus basalis of rats. , 1989, Behavioral neuroscience.

[84]  T. Stone,et al.  NMDA receptors and ligands in the vertebrate CNS , 1988, Progress in Neurobiology.

[85]  R. Schwarcz,et al.  Localization of quinolinic acid metabolizing enzymes in the rat brain. immunohistochemical studies using antibodies to 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase , 1988, Neuroscience.

[86]  R. Schwarcz,et al.  Quinolinic acid metabolism in the rat brain. Immunohistochemical identification of 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase in the hippocampal region , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[87]  R. Schwarcz,et al.  Immunohistochemical identification of quinolinic acid phosphoribosyltransferase in glial cultures from rat brain , 1988, Neuroscience Letters.

[88]  R. Schwarcz,et al.  Quinolinic acid phosphoribosyltransferase: preferential glial localization in the rat brain visualized by immunocytochemistry. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[89]  O. Hayaishi,et al.  Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase. , 1986, The Journal of biological chemistry.

[90]  R. Beninger,et al.  Quinolinic acid neurotoxicity in the nucleus basalis antagonized by kynurenic acid , 1985, Neurobiology of Aging.

[91]  R. Schwarcz,et al.  Purification of quinolinic acid phosphoribosyltransferase from rat liver and brain. , 1985, Biochimica et biophysica acta.

[92]  R. Schwarcz,et al.  Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid , 1984, Neuroscience Letters.

[93]  T. Stone,et al.  Pharmacology and regional variations of quinolinic acid-evoked excitations in the rat central nervous system. , 1983, The Journal of pharmacology and experimental therapeutics.

[94]  R. Schwarcz,et al.  Differential vulnerability of central neurons of the rat to quinolinic acid , 1983, Neuroscience Letters.

[95]  R. Schwarcz,et al.  Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. , 1983, Science.

[96]  D. Bender,et al.  The preferred route of kynurenine metabolism in the rat. , 1982, Biochimica et biophysica acta.

[97]  T. Stone,et al.  Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. , 1981, European journal of pharmacology.

[98]  B. Brew,et al.  Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef and Tat , 2011, Journal of NeuroVirology.

[99]  B. Brew,et al.  Involvement of quinolinic acid in aids dementia complex , 2009, Neurotoxicity Research.

[100]  B. Brew,et al.  Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons , 2005, Glia.

[101]  A. Cesura,et al.  Expression of the kynurenine enzymes in macrophages and microglial cells: regulation by immune modulators , 2005, Amino Acids.

[102]  I. Lapin,et al.  Excitatory effects of kynurenine and its metabolites, amino acids and convulsants administered into brain ventricles: Differences between rats and mice , 2005, Journal of Neural Transmission.

[103]  E. Ragazzi,et al.  Kynurenine pathway enzymes in different species of animals. , 2003, Advances in experimental medicine and biology.

[104]  B. Brew,et al.  Quinolinic acid in the pathogenesis of Alzheimer's disease. , 2003, Advances in experimental medicine and biology.

[105]  E. Ragazzi,et al.  Tryptophan metabolism along the kynurenine pathway in rats. , 2003, Advances in experimental medicine and biology.

[106]  E. Ragazzi,et al.  Tryptophan metabolism in rabbits. , 2003, Advances in experimental medicine and biology.

[107]  E. Ragazzi,et al.  Enzyme activities along the kynurenine pathway in mice. , 2003, Advances in experimental medicine and biology.

[108]  B. Brew,et al.  Expression of the kynurenine pathway enzymes in human microglia and macrophages. , 2003, Advances in experimental medicine and biology.

[109]  E. Ragazzi,et al.  Kynurenine pathway enzymes in guinea pigs. , 2003, Advances in experimental medicine and biology.

[110]  T. Stone,et al.  Endogenous neurotoxins from tryptophan. , 2001, Toxicon : official journal of the International Society on Toxinology.

[111]  B. Brew,et al.  Kynurenine pathway metabolism in human astrocytes. , 1999, Advances in experimental medicine and biology.

[112]  B. Brew,et al.  Quinolinic acid production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. , 1997, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[113]  K. Goda,et al.  Quinolinic acid and active oxygens. Possible contribution of active Oxygens during cell death in the brain. , 1996, Advances in experimental medicine and biology.

[114]  K. Goda,et al.  Quinolinic Acid and Active Oxygens , 1996 .